anti-FPRL1 C-terminal antibody product blog
Tags: Antibody; Monoclonal Antibody; FPRL1 C-terminal; anti-FPRL1 C-terminal antibody;
The FPRL1 C-terminal n/a (Catalog #MBS592224) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The mAb anti-Human FPRL1 C-terminal reacts with Human. Others not tested and may cross-react with other species as described in the data sheet. MyBioSource\'s FPRL1 C-terminal can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB).ELISA: Reactive to the C-terminal amino acid sequence (SASPPAETELQAM) on FPRL1 in indirect ELISA. Researchers should empirically determine the suitability of the FPRL1 C-terminal n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the mAb anti-Human FPRL1 C-terminal with the following immunoassay(s):
Testing Data
Mouse monoclonal antibody against the C-terminal amino acid sequence on human formyl peptide receptor-like 1 (FPRL-1).
Target Protein: Human formyl peptide receptor-like 1
Immunogen: A short peptide corresponding to the C-terminal amino acid sequence (SASPPAETELQAM) on FPRL1 was conjugated with KLH for immunization.
Myeloma: Sp2/0-Ag14
Light Chain: Kappa
Reconstitution: Double distilled water is recommended to adjust the final concentration to 1.00mg/mL. Research Area: G-protein coupled membrane receptor, chemotaxis and Alzheimer\'s disease. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing FPRL1 C-terminal are readily searchable from our website. Different antibodies against the same target such as FPRL1 C-terminal may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.